Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2014 1
2015 1
2016 7
2017 1
2019 3
2020 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

18 results
Results by year
Filters applied: . Clear all
Page 1
Tumour heterogeneity: principles and practical consequences.
Stanta G, Jahn SW, Bonin S, Hoefler G. Stanta G, et al. Among authors: jahn sw. Virchows Arch. 2016 Oct;469(4):371-84. doi: 10.1007/s00428-016-1987-9. Epub 2016 Jul 13. Virchows Arch. 2016. PMID: 27412632 Review.
GIRK1 triggers multiple cancer-related pathways in the benign mammary epithelial cell line MCF10A.
Schratter G, Scheruebel S, Langthaler S, Ester K, Pelzmann B, Ghaffari-Tabrizi-Wizsy N, Rezania S, Gorischek A, Platzer D, Zorn-Pauly K, Ahammer H, Prokesch A, Stanzer S, Devaney TTJ, Schmidt K, Jahn SW, Prassl R, Bauernhofer T, Schreibmayer W. Schratter G, et al. Among authors: jahn sw. Sci Rep. 2019 Dec 17;9(1):19277. doi: 10.1038/s41598-019-55683-w. Sci Rep. 2019. PMID: 31848385 Free PMC article.
Inferring expressed genes by whole-genome sequencing of plasma DNA.
Ulz P, Thallinger GG, Auer M, Graf R, Kashofer K, Jahn SW, Abete L, Pristauz G, Petru E, Geigl JB, Heitzer E, Speicher MR. Ulz P, et al. Among authors: jahn sw. Nat Genet. 2016 Oct;48(10):1273-8. doi: 10.1038/ng.3648. Epub 2016 Aug 29. Nat Genet. 2016. PMID: 27571261
Profiling of circulating tumor DNA and tumor tissue for treatment selection in patients with advanced and refractory carcinoma: a prospective, two-stage phase II Individualized Cancer Treatment trial.
Riedl JM, Hasenleithner SO, Pregartner G, Scheipner L, Posch F, Groller K, Kashofer K, Jahn SW, Bauernhofer T, Pichler M, Stöger H, Berghold A, Hoefler G, Speicher MR, Heitzer E, Gerger A. Riedl JM, et al. Among authors: jahn sw. Ther Adv Med Oncol. 2021 Feb 27;13:1758835920987658. doi: 10.1177/1758835920987658. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33717225 Free PMC article.
MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors.
Schwarzenbacher D, Klec C, Pasculli B, Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H, Wulf-Goldenberg A, Stanzer S, Rinnerthaler G, Stoeger H, Bauernhofer T, Haybaeck J, Hoefler G, Jahn SW, Parrella P, Calin GA, Pichler M. Schwarzenbacher D, et al. Among authors: jahn sw. Breast Cancer Res. 2019 Feb 1;21(1):20. doi: 10.1186/s13058-019-1104-5. Breast Cancer Res. 2019. PMID: 30709367 Free PMC article.
Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.
Singer CF, Filipits M, Jahn SW, Abete L, Jakesz R, Greil R, Bauernhofer T, Kwasny W, Seifert M, Fitzal F, Kastner M, Schmitt M, Moinfar F, Gnant M. Singer CF, et al. Among authors: jahn sw. Breast. 2019 Aug;46:101-107. doi: 10.1016/j.breast.2019.05.007. Epub 2019 May 3. Breast. 2019. PMID: 31132475
KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients.
Kammerer S, Sokolowski A, Hackl H, Platzer D, Jahn SW, El-Heliebi A, Schwarzenbacher D, Stiegelbauer V, Pichler M, Rezania S, Fiegl H, Peintinger F, Regitnig P, Hoefler G, Schreibmayer W, Bauernhofer T. Kammerer S, et al. Among authors: jahn sw. Oncotarget. 2016 Dec 20;7(51):84705-84717. doi: 10.18632/oncotarget.13224. Oncotarget. 2016. PMID: 27835900 Free PMC article.
18 results